Guinea Bissau: Guinea-Bissau Cancels Controversial US-Funded Hepatitis B Vaccine Trial on Newborns
Newborn babies in Guinea-Bissau will not be enrolled in a hepatitis B vaccine trial after the government cancelled the study in response to international pressure. Critics had raised serious concerns that the trial was unethical and potentially exploitative, and those voices appear to have carried weight with health authorities.
The proposed trial was funded by the United States and had drawn scrutiny from researchers, bioethicists, and advocacy groups who questioned whether it met the standards required for studies involving such a vulnerable population. The backlash crossed borders quickly, turning what began as a local health policy decision into a global conversation about research ethics on the African continent.
Guinea-Bissau's decision to pull the plug signals something important: that African governments are increasingly willing to push back when outside-funded research raises red flags. The story is far from over, though. Questions about who designs these trials, who benefits from them, and who bears the risk are only getting louder.
Originally published by AllAfrica · info@allafrica.com (allAfrica).